Eupraxia Pharmaceuticals Inc
TSX:EPRX
Relative Value
There is not enough data to reliably calculate the relative value of EPRX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
EPRX Competitors Multiples
Eupraxia Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CA |
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
136.8m CAD | 0 | -4.8 | -4.3 | -4.3 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286B USD | 5.3 | 59.3 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.1B USD | 5.9 | 24.9 | 17.9 | 26.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.8B USD | 10.4 | 28.3 | 22.7 | 23.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.9B USD | 7.8 | 26 | 17.5 | 19.2 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.4 | 21.5 | 26.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.4B USD | 2.9 | 165.9 | 6.7 | 8.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.3B USD | 7 | -10.1 | -10.9 | -9.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.2B USD | 3.2 | 26.8 | 13.7 | 17.2 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |